Recognition by Microsoft as a Valuable Use Case
We are thrilled to announce that we, as one of the leading providers of technologies for risk-based quality management in the biopharma industry, have been recognized by Microsoft as a valuable use case. Our MyRBQM software-as-a-service (SaaS) solution helps pharmaceutical companies comply with regulations for clinical trials by identifying and evaluating critical data and processes and implementing preventive and corrective measures.
The challenge of dirty data in clinical trials
One of the biggest challenges in the field of clinical trials is dealing with dirty data, which can lead to inconsistencies and errors, potentially causing trials to be terminated. Our solution addresses this challenge by monitoring all potential risks and guaranteeing high data quality by harmonizing data provided by customers and analyzing it for performance, speed, risks, and quality.
Scalable and secure technologies with Azure Virtual Machines
To meet the growing demand for our solution and reduce IT costs, we rely on a suite of Azure services for our software-as-a-service solution, the MyRBQM Portal. Azure Virtual Machines provide us with scalable and secure technologies, allowing us to handle large quantities of data and multiple configurations.
Innovations in the field of Risk-Based Quality Management
We are honored that Microsoft has chosen to feature our use case on their website. This recognition is a testament to the dedication and hard work of our team in developing a solution that helps pharmaceutical companies achieve the highest possible data quality in clinical trials. We are excited to share our story with Microsoft’s target audiences and continue to innovate in the field of risk-based quality management in the biopharma industry.
Find out how Microsoft Azure addresses the challenge of large quantities of data and little scalability in clinical trials. Read our customer story on Microsoft’s website now!
Erfahren Sie, wie Microsoft Azure die Herausforderungen von großen Datenmengen und geringer Skalierbarkeit in klinischen Studien meistert. Lesen Sie jetzt unsere Kundengeschichte auf der Website von Microsoft!
